These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38581198)

  • 1. Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
    Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
    JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
    Martin RM; Donovan JL; Turner EL; Metcalfe C; Young GJ; Walsh EI; Lane JA; Noble S; Oliver SE; Evans S; Sterne JAC; Holding P; Ben-Shlomo Y; Brindle P; Williams NJ; Hill EM; Ng SY; Toole J; Tazewell MK; Hughes LJ; Davies CF; Thorn JC; Down E; Davey Smith G; Neal DE; Hamdy FC;
    JAMA; 2018 Mar; 319(9):883-895. PubMed ID: 29509864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
    Auvinen A; Tammela TLJ; Mirtti T; Lilja H; Tolonen T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Natunen K; Nevalainen J; Raitanen J; Ronkainen J; van der Kwast T; Riikonen J; Pétas A; Matikainen M; Taari K; Kilpeläinen T; Rannikko AS;
    JAMA; 2024 May; 331(17):1452-1459. PubMed ID: 38581254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
    Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
    JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of Screening for Prostate Cancer Among Men Who Use Statins.
    Vettenranta A; Murtola TJ; Raitanen J; Raittinen P; Talala K; Taari K; Stenman UH; Tammela TLJ; Auvinen A
    JAMA Oncol; 2022 Jan; 8(1):61-68. PubMed ID: 34817559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
    Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
    JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
    Turner EL; Metcalfe C; Donovan JL; Noble S; Sterne JA; Lane JA; Avery KN; Down L; Walsh E; Davis M; Ben-Shlomo Y; Oliver SE; Evans S; Brindle P; Williams NJ; Hughes LJ; Hill EM; Davies C; Ng SY; Neal DE; Hamdy FC; Martin RM;
    Br J Cancer; 2014 Jun; 110(12):2829-36. PubMed ID: 24867688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
    Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
    JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Kovac E; Carlsson SV; Lilja H; Hugosson J; Kattan MW; Holmberg E; Stephenson AJ
    JAMA Netw Open; 2020 Jan; 3(1):e1919284. PubMed ID: 31940039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
    Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
    Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
    Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
    Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical Trials.
    King MT; Chen MH; Collette L; Neven A; Bolla M; D'Amico AV
    JAMA Netw Open; 2021 May; 4(5):e2111092. PubMed ID: 33999161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.